These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27906610)

  • 1. Infectious Complications after Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy.
    Arslan NC; Sokmen S; Avkan-Oguz V; Obuz F; Canda AE; Terzi C; Fuzun M
    Surg Infect (Larchmt); 2017; 18(2):157-163. PubMed ID: 27906610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies.
    Dreznik Y; Hoffman A; Hamburger T; Ben-Yaacov A; Dux Y; Jacoby H; Berger Y; Nissan A; Gutman M
    Surgeon; 2018 Oct; 16(5):278-282. PubMed ID: 29429947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
    Sin EI; Chia CS; Tan GHC; Soo KC; Teo MC
    Int J Hyperthermia; 2017 Sep; 33(6):690-695. PubMed ID: 28540777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
    Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
    Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
    van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
    Vaira M; Robella M; Mellano A; Sottile A; De Simone M
    Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score.
    Malfroy S; Wallet F; Maucort-Boulch D; Chardonnal L; Sens N; Friggeri A; Passot G; Glehen O; Piriou V
    Surg Oncol; 2016 Mar; 25(1):6-15. PubMed ID: 26979635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
    Smibert OC; Slavin MA; Teh B; Heriot AG; Penno J; Ismail H; Thursky KA; Worth LJ
    Support Care Cancer; 2020 Jun; 28(6):2745-2752. PubMed ID: 31712951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia.
    Wang TY; Chen CY; Lu CH; Chen MC; Lee LW; Huang TH; Hsieh MC; Chen CJ; Yu CM; Chuang HC; Liao TT; Tseng CW; Huang WS
    Int J Hyperthermia; 2018 May; 34(3):328-335. PubMed ID: 28562119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
    Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
    Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
    Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
    Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy.
    Cascales Campos P; Martinez Insfran LA; Wallace D; Gil J; Gil E; Gonzalez Gil A; Martínez J; Alonso Romero JL; Gonzalez Sanchez R; Parrilla P
    Clin Transl Oncol; 2020 Jun; 22(6):852-859. PubMed ID: 31392644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
    Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothermia Is Associated with Surgical Site Infection in Cytoreductive Surgery with Hyperthermic Intra-Peritoneal Chemotherapy.
    Eng OS; Raoof M; O'Leary MP; Lew MW; Wakabayashi MT; Paz IB; Melstrom LG; Lee B
    Surg Infect (Larchmt); 2018; 19(6):618-621. PubMed ID: 30044187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis.
    Simkens GA; van Oudheusden TR; Luyer MD; Nienhuijs SW; Nieuwenhuijzen GA; Rutten HJ; de Hingh IH
    Ann Surg Oncol; 2015 Aug; 22(8):2656-62. PubMed ID: 25515200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.